Skip to main content

Table 2 CPV Case Details

From: Impact of a protein-based assay that predicts prostate cancer aggressiveness on urologists’ recommendations for active treatment or active surveillance: a randomized clinical utility trial

CPV Case

Presenting History

Stage

Gleason

Cores

PSA

NCCN Risk Category

PBA score

PBA Risk Category

Preferred Option

1

Active 60 year old M with increasing urinary frequency

T1c

3 + 3

2_12 (<50%)

<10

Very Low

15

Low

AS

2

Sedentary 78 year old M with hematuria

T1c

3 + 3

4_12 (<50%)

7.1

Very Low

15

Low

AS

3

Moderately active 73 year old M with urinary frequency and hesitancy

T2a

3 + 4

3_12 (20% tumor in 4 s)

14

Intermediate

17

Low

AS

4

Quite active 57 year old M with erectile dysfunction and recent prostatitis

T2a

3 + 4

7_12

21

High

17

Low

AS

5

Moderately active 55 year old M with rising serum PSA levels

T1c

3 + 3

4_12

9.8

Very Low

35

Intermediate

AS

6

63 year old M, no longer active due to knee osteoarthritis, with suspicious digital rectal examination

T1c

3 + 3

6_12

8.9

Low

60

Intermediate

AT

7

Active 62 year old M with gross hematuria

T1c

3 + 4

3_12 (10% showing)

10.4

Intermediate

20

Low

AS

8

Lightly active 75 year old M seen for follow-up of suspicious nodularity on prostate

T2a

3 + 4

6_12

8.7

Intermediate

77

High

AT

9

Moderately active77 year old M seen in referral for nodule on prostate and high serum PSA

T2a

3 + 4

6_12

22.1

High

77

High

AT

  1. PBA protein-based assay